VP at Acadia Pharmaceuticals, pled guilty to insider trading, avoiding a $1.3M loss by illicitly selling shares ahead of a negative FDA news impact. He faces sentencing in May 2025.

A former pharmaceutical executive traded on nonpublic information about an antipsychotic drug’s development, avoiding $1.3 ...

The former vice president of a Carmel Valley pharmaceutical company pleaded guilty Friday to a federal securities fraud count.

George Demos, 64, formerly of Acadia Pharmaceuticals Inc., admitted selling more than 60,000 company shares just before news broke regarding an issue with one of the company's products ...

The former CEO of Acadia Pharmaceuticals Inc., headquartered in Sorrento Valley, pleaded guilty Friday to insider trading.

Demos, a medical doctor who was the Vice President of Drug Safety and Pharmacovigilance and member of the drug label team at ...

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...

The former vice president of a San Diego-based pharmaceutical company pleaded guilty Friday to a federal securities fraud count for insider trading ... 64, formerly of Acadia Pharmaceuticals ...